Pharmascience

Type: Company
Name: Pharmascience
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Pendopharm Updates on Health Canada's Approval of IBAVYR

Quebec-based Pendopharm, a division of Pharmascience Inc., reported Health Canada approval and market availability of IBAVYRTM (ribavirin tablets), the first stand-alone oral ribavirin for the treatment of chronic hepatitis C virus (HCV) infections in ... [Published Individual.com - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

BRIEF-PAION completes private placement with Pendopharm's European affiliate Pharmascience International Ltd

9:55am BSTJuly 17(Reuters) - PAION AG :* Says will issue about 1.27 million new shares for EUR 3.1463 per share with a total value of EUR 4 million* Says will issue shares in private placement to Pendopharm's European affiliate Pharmascience International ... [Published Reuters UK - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Syrian Arab Republic: Syrian man can smile again thanks to treatment

Source: Health Partners International of CanadaCountry: Syrian Arab Republic A Syrian man in his early 20s was injured during the civil war in his country when a bomb hit his neighbourhood. Shrapnel had struck his neck and made him a quadriplegic. “I ... [Published ReliefWeb - Latest Updates - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Canada Health Approves IBAVYR: A New Boost For Gilead’s Sovaldi

Health Canada has approved the marketing of Pharmascience’s drug IBAVYR (ribavirin tablets) in Canada. IBAVYR is the first standalone oral treatment for chronic hepatitis C. The medication has been approved for use with other agents like Gilead Science’s ... [Published Bidness Etc - Jul 17 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 5 reports

Pendopharm gets Health Canada approval for hepatitis C drug Ibavyr

Pendopharm, a division of Pharmascience, has secured Health Canada approval and market availability of IBAVYR (ribavirin tablets), the first stand-alone oral ribavirin for the treatment of chronic hepatitis C virus (HCV) infections in Canada.The drug ... [Published Pharmaceutical Business Review - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Oxford Pharmascience appoints new non-exec

Oxford Pharmascience ( LON:OXP ) announced it has appointed veteran investor Karl Robertson Van Horn to its board as a non-executive director. Van Horne, age 79, has had a distinguished multinational career in senior positions across investment management, ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Woodford reveals his full portfolio

Star fund manager Neil Woodford recently revealed the top ten holdings in the new Woodford Equity Income fund.Now he’s gone one step further and announced the holdings in full on his fund website . Woodford intends that this will be updated every mon ... [Published Money Week - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Neil Woodford's full portfolio revealed

(Update) Star fund manager Neil Woodford has just under a third of his fund in healthcare stocks, alongside significant weightings in consumer goods companies and financials.His eponymous fund firm is seeking to fight opacity in the fund industry by disclosing ... [Published Wealth Manager - Jul 14 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

PendoPharm partners with PAION

PendoPharm, Inc., a division of pharmaceutical company Pharmascience, Inc., and PAION AG, a Germany-based biopharmaceutical company, have entered into a license agreement for PAION's drug candidate, Remimazolam, a short-acting general anaesthetic and ... [Published Individual.com - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

News in brief: Robert Walters, Computacenter, Wincanton, Software Radio Technology, Seeing Machines, Oxford Pharmascience

Upgrades to drive WaltersRecruitment agent Robert Walters (RWA) says the UK jobs market recovery has only just begun, adding that employment gains historically lag economic growth. Analysts are now starting to upgrade earnings forecasts, helped by .. ... [Published Shares Magazine - Jul 10 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Pharma in brief - Federal Court of Appeal overturns Federal Court decision and dismisses application for prohibition order

Case : Pharmascience Inc. v AstraZeneca Canada Inc. et al 2014 FCA 133Nature of case : Appeal of a s.6 prohibition order pursuant to the PM(NOC) RegulationsDate of decision : May 22, 2014 (public reasons available as of June 10, 2014)SummaryPharmascience ... [Published Norton Rose Canada - Jul 03 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 3 reports

UPDATE - Oxford Pharmascience pleased with "fantastic" NSAID trial result

---ADDS BROKER & CEO COMMENTS PLUS SHARE PRICE REACTION--- Oxford Pharmascience ( LON:OXP ) said the primary and second end points were met in its pilot clinical study of OXP001, its non-steroidal anti-inflammatory drug (NSAID). Oxford, which specialises ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]

Quotes

...in Canada," said Jordan Feld, MD, MPH, Staff Hepatologist, Toronto Western Hospital, Department of Medicine, Division of Gastroenterology. "Interferon has been the main stumbling block to treatment in the past. New regimens without interferon are a huge advance, giving us higher cure rates and shortened treatment duration with a lot fewer side effects. This gives us our best opportunity to successfully treat and cure Canadians with hepatitis C" added Dr. Feld
...Ajani said there are many reasons why doing business in Italy is difficult but focused on one particular problem. "If you are not a friend of a friend, everything is difficult" he said. Having increased sales by 400% from 2006 to 2013, Cosmo is now looking to expand sales in the U S through its deal with Salix and bring its...
"Now, PENDOPHARM will work closely with the provinces to ensure patients have access to IBAVYR and all-oral treatments as quickly as possible, in order to achieve high cure rates while improving quality of life." Latest News
Van Horn commented: "I am pleased to join the board of Oxford Pharmascience and I look forward to applying my experience in assisting the future development of the company."

More Content

All (56) | News (47) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Pendopharm Updates on Health Canada's Approval ... [Published Individual.com - Jul 21 2014]
BRIEF-PAION completes private placement with Pe... [Published Reuters UK - Jul 18 2014]
Syrian Arab Republic: Syrian man can smile agai... [Published ReliefWeb - Latest Updates - Jul 18 2014]
U.K. gov names ex-biotech VC as life sci chief,... [Published FierceBiotech - Jul 18 2014]
DGAP-Adhoc: PAION COMPLETES PRIVATE PLACEMENT W... [Published GlobeNewswire: Advertising News - Jul 17 2014]
Canada Health Approves IBAVYR: A New Boost For ... [Published Bidness Etc - Jul 17 2014]
Analysts’ Ratings Reiterations for July, 16th (... [Published American Banking News - Forex - Jul 16 2014]
Canada Approves Use of IBAVYR [Published Bidness Etc - Jul 16 2014]
Pendopharm gets Health Canada approval for hepa... [Published Pharmaceutical Business Review - Jul 16 2014]
Canada approves Pendopharm’s all-oral ribavirin... [Published Pharma Letter - Jul 16 2014]
Oxford Pharmascience appoints new non-exec [Published Proactiveinvestors United Kingdom RSS feed - Jul 16 2014]
Health Canada’s Approval of IBAVYR™ Enables Spe... [Published Pettinga Financial Advisors - Jul 15 2014]
Health Canada's Approval of IBAVYR(TM) Enables ... [Published CNBC - Jul 15 2014]
Health Canada’s Approval of IBAVYR™ Enables Spe... [Published Business Wire Health News - Jul 15 2014]
Woodford reveals his full portfolio [Published Money Week - Jul 14 2014]
Neil Woodford's full portfolio revealed [Published Wealth Manager - Jul 14 2014]
PendoPharm partners with PAION [Published Individual.com - Jul 10 2014]
News in brief: Robert Walters, Computacenter, W... [Published Shares Magazine - Jul 10 2014]
DGAP-News: PAION GRANTS LICENCE TO REMIMAZOLAM ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
Pharma in brief - Federal Court of Appeal overt... [Published Norton Rose Canada - Jul 03 2014]
Research Analysts’ Ratings Reiterations for Jun... [Published American Banking News - Jun 17 2014]
UPDATE - Oxford Pharmascience scores line exten... [Published Proactiveinvestors United Kingdom website - Jun 17 2014]
OXP okays Brazil line extension for new version... [Published Stock Market Wire - Jun 17 2014]
Chew Product - Line Extension [Published MoneyAM - Jun 17 2014]
Oxford Pharmascience scores line extension in B... [Published Proactiveinvestors United Kingdom RSS feed - Jun 17 2014]
UPDATE - Oxford Pharmascience pleased with "fan... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]
UPDATE - Oxford Pharmascience unveils positive ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]
Oxford Pharmascience unveils positive NSAID tri... [Published Proactiveinvestors United Kingdom website - Jun 02 2014]
Major Discovery on the Mechanism of Drug Resist... [Published Science Daily - May 28 2014]
Oxehealth receives ?2m of investment [Published TrustNet - May 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Syrian Arab Republic: Syrian man can smile agai... [Published ReliefWeb - Latest Updates - Jul 18 2014]
Source: Health Partners International of CanadaCountry: Syrian Arab Republic A Syrian man in his early 20s was injured during the civil war in his country when a bomb hit his neighbourhood. Shrapnel had struck his neck and made him a quadriplegic. “I ...
Health Canada’s Approval of IBAVYR™ Enables Spe... [Published Business Wire Health News - Jul 15 2014]
MONTREAL--(BUSINESS WIRE)--Quebec-based Pendopharm, a division of Pharmascience Inc., today announced Health Canada approval and market availability of IBAVYRTM (ribavirin tablets), the first stand-alone oral ribavirin for the treatment of chronic hepatitis ...
UPDATE - Oxford Pharmascience scores line exten... [Published Proactiveinvestors United Kingdom website - Jun 17 2014]
---ADDS BROKER COMMENT AND SHARE PRICE--- Oxford Pharmascience ( LON:OXP ) has agreed a line extension in Brazil with its partner Aché Pharmaceuticos. The UK company specialises in redeveloping medicines to make them better, safer and easier to take, ...
Oxford Pharmascience unveils positive NSAID tri... [Published Proactiveinvestors United Kingdom website - Jun 02 2014]
Oxford Pharmascience ( LON:OXP ) said the primary and second end points were met in its pilot clinical study of OXP001, its non-steroidal anti-inflammatory drug (NSAID). Oxford, which specialises in reformulating drugs to make them better, safer and ...
Pendopharm Announces Priority Review of New The... [Published Business Wire Health News - Mar 31 2014]
MONTREAL--(BUSINESS WIRE)--New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest options, Pendopharm, a division ...
1 2

Press Releases

sort by: Date | Relevance
DGAP-Adhoc: PAION COMPLETES PRIVATE PLACEMENT W... [Published GlobeNewswire: Advertising News - Jul 17 2014]
DGAP-News: PAION GRANTS LICENCE TO REMIMAZOLAM ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.